Yinxin He

Sun Yat-sen University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Jinsheng Zeng

Nanchang University

Jianle Li

Sun Yat-sen University

Shihui Xing

Sun Yat-sen University

Yicong Chen

Sun Yat-sen University

Qingfeng Lei

Sun Yat-sen University

Jian Yu

Nanjing Medical University

Mengshi Liao

Sun Yat-sen University

Chao Dang

The First Affiliated Hospital, Sun Yat-sen University

Yuhua Fan

Sun Yat-sen University

Jingjing Li

Sun Yat-sen University

Cooperative Institutions

Sun Yat-sen University

The First Affiliated Hospital, Sun Yat-sen University

Guangdong Pharmaceutical University

Dalian University of Technology

First Affiliated Hospital of Jinan University

First Affiliated Hospital of GuangXi Medical University

Guangxi Medical University

Capital Medical University

Sun Yat-sen University Cancer Center

University Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Efficacy and safety of agomelatine versus SSRIs/SNRIs for post-stroke depression: a systematic review and meta-analysis of randomized controlled trials

International Clinical Psychopharmacology (2023)

Yicong Chen Jianle Li Mengshi Liao Yinxin He Chao Dang

Agomelatine is effective in the treatment of depression, but its effect for post-stroke depression (PSD) remains unclear. This study was conducted to compare the efficacy and safety of agomelatine versus SSRIs/SNRIs in treating PSD. We systematically searched Embase, PubMed, Cochrane Library, WanFang Data, China National Knowledge Infrastructure, and Cqvip databases for double-blind randomized controlled studies comparing the efficacy and safety of agomelatine versus SSRIs/SNRIs for PSD until December 2022. The primary efficacy endpoint was the Hamilton Depression Rating Scale (HAMD) score, and the primary safety endpoint was the incidence of overall adverse reactions. Nine studies comprising 857 patients with PSD were included. After 6-12 weeks of treatment, the HAMD score ( P = 0.16) and the overall response rates ( P = 0.20) in the agomelatine group were comparable to that in the SSRIs/SNRIs group. Participants treated with agomelatine achieved higher Barthel Index scores compared with the SSRIs/SNRIs group ( P = 0.02). There was a significantly lower incidence of overall adverse reactions ( P = 0.008) and neurological adverse reactions ( P < 0.0001) in the agomelatine group. The efficacy of agomelatine for treating PSD is probably comparable to that of SSRIs/SNRIs, and it may improve stroke outcomes with better safety.

Agomelatine

Depression

Stroke

Post-Stroke Depression

Clinical endpoint

10.1097/yic.0000000000000509

Cite

Citations (4)

Certification of stroke centers at primary hospitals and the improvement of thrombolysis n South China during 2020–2022

European Stroke Journal (2024)

Yicong Chen Qingfeng Lei Jiaoxing Li Jianle Li Yinxin He

IVT use declined globally in 2020 due to the Corona Virus Disease 2019 (COVID-19) pandemic, but it increased in South China. This study was conducted to evaluate the association of establishing Stroke Prevention Centers (SPCs) at primary hospitals with IVT increase in South China.

Stroke

Pandemic

Primary Prevention

2019-20 coronavirus outbreak

10.1177/23969873231223062

Cite

Citations (0)